I. COMMENCED TRADING IN AUGUST

Company (Symbol)

Date Filed (M)

Date Comm.

Shares/
Units (M)

Price

Shares
Out

Lead, Other
Underwriters

Gross
(M)

Post-
Offering Market
Cap (M)

INITIAL OFFERINGS

There were no initial public offerings conducted in August.

Total: $0M

Number of IPOs in August: 0

Average value of August IPOs: $0M

Number of IPOs in 2003: 0

Total raised in IPOs in 2003: $0M

Average value of IPOs in 2003: $0M

FOLLOW-ON OFFERINGS

Company
(Symbol)#

Date
Filed

Date
Comm.

Shares/
Units (M)

Price

Shares
Out
(M)@

Lead, Other
Underwriters

Gross
(M)

Post-
Offering
Market
Cap
(M)%

EPIX Medical
Inc. (EPIX)1

7/28/03

8/7/03

4.645S

$15

21.9

SG Cowen Securities Wells Fargo Securities Needham & Co. WR Hambrecht + Co.

$69.7

$328.5

Esperion
Therapeutics
Inc. (ESPR)2

7/14/03

8/1/03

4S

$16

33.5

Lehman Brothers Citigroup Global Markets Needham & Co. U.S. Bancorp Piper Jaffray SG Cowen

$64

$536

La Jolla
Pharmaceutical
Co. (LJPC)3

12/12/02

8/7/03

8.15S

$2.75

50.8

Pacific Growth Equities

$22.4

$139.7

MGI Pharma
Inc. (MOGN)4

6/17/03

8/8/03

5.1S

$35.50

30.7

Merrill Lynch (co-lead)
U.S. Bancorp Piper Jaffray (co-lead)
Lazard Freres C.E. Unterberg, Towbin

$181.05

$1,089.9

Total: $337.15M

Number of follow-on offerings in August: 4

Average value of August follow-ons: $84.29M

Number of follow-on offerings in 2003: 21

Total raised in follow-ons in 2003: $1,432.07M

Average value of follow-ons in 2003: $68.19M

Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

@ This column reflects the shares outstanding following the offering, when disclosed.

% Market capitalization calculated is based on the offering price.

1. EPIX raised $69.7M in the public offering of 4.645M shares, which includes the exercise of the overallotment option.

2. Esperion's underwriters have an overallotment option for 600,000 shares.

3. La Jolla raised about $22.4M through the public offering of 8.15M shares.

4. MGI's underwriters exercised their overallotment option for 660,000 shares, which is included in the value.

II. FILED AND PENDING

Company (Symbol/
Proposed Symbol)#*

Date
Filed

Shares/
Units
(M)

Price
Range

Shares
Out
(M)@

Lead, Other
Underwriters

Value
(M)

INITIAL OFFERINGS

Acusphere Inc.
(ACUS)1

8/21/03

3.75S

$13-$15

14.2

SG Cowen Securities
Thomas Weisel Partners
U.S. Bancorp Piper Jaffray
Friedman Billings Ramsey

$52.5

Aderis
Pharmaceuticals
(ADPX)2

8/28/03

N/A

N/A

N/A

Lehman Brothers (co-lead)
CIBC World Markets (co-lead) U.S. Bancorp Piper Jaffray

$75

Advancis
Pharmaceuticals
Corp. (AVNC)3

8/4/03

N/A

N/A

N/A

Lehman Brothers
Pacific Growth Equities

$86.25

CancerVax
Corp. (CNVX)4

8/15/03

N/A

N/A

N/A

Lehman Brothers
Thomas Weisel Partners
U.S. Bancorp Piper Jaffray

$115

Diversified
Biotech Holdings
Corp. (AMEX:DBH)5

7/25/03

2.5S

$4-$6

12.32

InvestPrivate Inc.
The Shemano Group

$12.5

Genitope Corp.
(GTOP)6

8/7/03

N/A

N/A

N/A

WR Hambrecht + Co.
Punk, Ziegel & Co.

$68.8

Myogen
Inc.7

8/28/03

N/A

N/A

N/A

Credit Suisse First Boston
J.P. Morgan Securities
CIBC World Markets
Lazard Freres

$75

Neurochem Inc.
(Canada; NRMX;
TSE:NRM)8

8/20/03

4.2S

C$14.48

(US$10.41)

27.8

UBS Securities
Banc of America Securities
RBC Dominion Securities
CIBC World Markets
Loewen, Ondaatje, McCutcheon
Orion Securities

US$43.7

Nitromed Inc.
(NTMD)9

8/21/03

N/A

N/A

N/A

Deutsche Bank Securities (co-lead) JP Morgan Securities (co-lead)
Pacific Growth Equities

$100

Pharmion Corp.
(PHRM)10

8/21/03

N/A

N/A

N/A

Morgan Stanley (co-lead)
JP Morgan Securities (co-lead)
Pacific Growth Equities
U.S. Bancorp Piper Jaffray

$86.3

TolerRx Inc.
(TLRX)11

8/27/03

N/A

N/A

N/A

J.P. Morgan Securities (co-lead)
S.G. Cowen Securities (co-lead)
Leerink Swann & Co.

$75

ViaCell Inc.
(VIAC)12

1/30/02

N/A

N/A

N/A

UBS Warburg
Banc of America Securities
U.S. Bancorp Piper Jaffray

$115

FOLLOW-ON OFFERINGS

Adolor Corp.
(ADLR)13

8/15/03

7.5S

$12.07

39.1

N/A

$90.525

Alteon Inc.
(AMEX:ALT)14

6/13/03

N/A

N/A

N/A

N/A

$100

Amgen Inc.
(AMGN)15

8/5/03

N/A

N/A

N/A

N/A

$1B

Ariad
Pharmaceuticals
Inc. (ARIA)16

7/3/03

7.5S

$4.275

N/A

N/A

$32.06

Biomira Inc.
(Canada; BIOM;
TSE:BRA)17

5/2/02

N/A

N/A

53.4

N/A

C$150
(US$97.84)

BioPure Corp.
(BPUR)18

3/6/03

10S

$3.84

N/A

N/A

$38.4

Cambridge
Antibody
Technology
Group plc (UK;
CATG; LSE:CAT)19

7/30/03

N/A

N/A

N/A

N/A

$175

Celgene Corp.
(CELG)20

12/21/01

N/A

N/A

75.6

N/A

$500

Cell Genesys Inc.
(CEGE)21

12/23/02

N/A

N/A

N/A

N/A

$150

Centrex Inc.
(OTC BB:CNEX)22

2/24/03

N/A

N/A

N/A

HD Brous & Co. Inc.

$20

Cepheid Inc.
(CPHD)23

12/21/01

N/A

N/A

26.56

N/A

$35

Cubist
Pharmaceuticals
Inc. (CBST)24

3/7/03

N/A

N/A

N/A

N/A

$75

Dendreon Corp.
(DNDN)25

1/22/03

N/A

N/A

N/A

N/A

$75

Dyax Corp.
(DYAX)26

7/15/03

N/A

N/A

N/A

N/A

$40

Encysive
Pharmaceuticals
Inc. (ENCY)27

8/21/03

N/A

N/A

N/A

N/A

$50

GenVec Inc.
(GNVC)28

12/19/02

N/A

N/A

N/A

N/A

$25

Geron Corp.
(GERN)29

1/30/02

N/A

N/A

N/A

N/A

$150

Hollis-Eden
Pharmaceuticals
Inc. (HEPH)30

7/25/03

5S

$14.39

N/A

N/A

$71.95

Immtech
International
Inc. (AMEX:IMM)31

8/28/03

1.5S

$18.01

N/A

N/A

$27.02

Introgen
Therapeutics
Inc. (INGN)32

8/11/03

N/A

N/A

N/A

N/A

$100

NaPro BioThera-
peutics Inc.
(NPRO)33

8/11/03

7.5S

$1.24
$8.06

N/A

N/A

$16.12

Neose
Technologies
Inc. (NTEC)34

6/23/03

N/A

N/A

N/A

N/A

$75

Neurocrine
Biosciences Inc.
(NBIX)35

6/9/03

N/A

N/A

N/A

N/A

$200

Neurogen Corp.
(NRGN)36

8/16/02

N/A

N/A

N/A

N/A

$75

Northfield
Laboratories
Inc. (NFLD)37

6/30/03

N/A

N/A

N/A

N/A

$50

Novavax Inc.
(NVAX)38

8/15/03

N/A

N/A

N/A

N/A

$50

Nuvelo Inc.
(NUVO)39

7/8/03

N/A

N/A

N/A

N/A

$50

Pain
Therapeutics
Inc. (PTIE)40

8/22/03

7.7S

$6.70

N/A

Citigroup Global Markets
CIBC World Markets
Leerink Swann ThinkEquity Partners

$51.6

Pharmos Corp.
(PARS)41

2/4/02

N/A

N/A

56.6

N/A

$25

Progenics
Pharmaceuticals
Inc. (PGNX)42

7/15/03

2.75S

$16.44

N/A

N/A

$45.21

SciClone
Pharmaceuticals
Inc. (SCLN)43

8/1/03

6S

$7.94

44.3

Jeffries & Co.
Harris Nesbitt Gerard
RBC Capital Markets

$47.64

StemCells Inc.
(STEM)44

3/8/02

15S

$2.52

25.8

N/A

$37.8

Targeted
Genetics Corp.
(TGEN)45

8/11/03

11.6S

$1.77

N/A

N/A

$20.53

Tularik Inc.
(TLRK)46

8/14/01

N/A

N/A

49.2

N/A

$250

VaxGen Inc.
(VXGN)47

11/7/02

N/A

N/A

N/A

N/A

$150

Vical
Inc. (VICL)48

8/15/03

N/A

N/A

N/A

N/A

$50

XOMA Ltd.
(XOMA)49

8/14/03

13S

$7.97

83.6

N/A

$103.6

ZymoGenetics
Inc. (ZGEN)50

7/28/03

N/A

N/A

N/A

N/A

$150

Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

* Stock symbols for companies seeking to complete IPOs are proposed.

@ This column reflects the shares outstanding following the offering, when disclosed.

N/A = Not available, applicable or reported.

AMEX = American Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange.

1. Acusphere filed for an IPO that would raise $52.5M based on the sale of 3.75M shares at $14 each, the midpoint of the expected price range.

2. Aderis filed for an IPO to raise $75M. It had filed in January 2002 for an IPO, but later withdrew that filing.

3. Advancis filed for an IPO in an effort to raise $86.25M.

4. CancerVax filed for an IPO to raise $115M. It did not specify the number of shares or the share price.

5. Diversified filed for a proposed IPO. The value, $12.5M, is based on the sale of 2.5M shares at $5 a share, the midpoint of the expected price range. The underwriters have an overallotment option for 375,000 shares.

6. Genitope filed for an IPO to raise $68.8M. It did not disclose the number of shares it plans to offer or the price range.

7. Myogen filed for an IPO to raise $75M.

8. Neurochem filed for an IPO in the U.S. Based on its closing share price on the Toronto Stock Exchange on Aug. 18 of US$10.41, the offering of 4.2M shares in the U.S. IPO would raise about US$43.7M.

9. Nitromed filed for an IPO to raise $100M. It did not specify the number of shares it would offer or the price range.

10. Pharmion filed for an IPO to raise about $86.3M.

11. TolerRx filed for an IPO to raise $75M.

12. ViaCell filed for a $115M IPO. No further details were disclosed.

13. Adolor filed a shelf registration statement to offer and sell up to 7.5M shares of common stock from time to time. The value is based on the proposed maximum offering price.

14. Alteon filed a shelf registration statement to offer and sell, from time to time, up to $100M of securities.

15. Amgen filed a shelf registration to sell up to $1B worth of debt securities, common stock, preferred stock, warrants, securities purchase contracts, securities purchase units and depositary shares.

16. Ariad filed a shelf registration statement for up to 7.5M shares of common stock, which would raise $32.06M based on the proposed maximum aggregate offering price.

17. Biomira filed for a US$97.84M shelf prospectus in Canada. The company raised US$3.7M in a private placement in May.

18. BioPure registered to sell up to 10M shares of common stock through a shelf registration. Based on the March 6, 2003, closing stock price of $3.84, the offering would raise $38.4M. Biopure raised $7.3M in private placements conducted in May, and $17.2M in one conducted in July.

19. Cambridge Antibody registered to sell up to $175M in common stock or American depository shares from time to time.

20. Celgene filed a universal shelf registration statement to offer and sell common stock, debt securities and convertible debt securities, up to a total value of $500M. In May, Celgene privately placed $400M in convertible notes.

21. Cell Genesys filed a shelf registration statement allowing it to issue, from time to time, up to $150M of securities.

22. Centrex plans to raise $20M with HD Brous as its managing underwriter.

23. Cepheid filed a shelf registration statement to offer and sell up to $35M of its common stock, preferred stock, debt securities and warrants. The company privately placed $5M in stock in February, and $10M in August.

24. Cubist filed a shelf registration statement to sell up to $75M in stock.

25. Dendreon filed a shelf registration with the SEC to sell $75M in stock from time to time. Dendreon raised $30.7M in a private placement in June.

26. Dyax filed a shelf registration statement with the SEC to issue up to $40M worth of common stock, debt securities and other types of securities from time to time.

27. Encysive filed a shelf registration statement to offer and sell up to $50M of its common stock, from time to time, in one or more offerings.

28. GenVec filed a $25M shelf registration statement with the SEC.

29. Geron filed a prospectus for the sale of up to $150M in debt securities, common or preferred stock and warrants. Geron raised $18.4M in a private placement in April.

30. Hollis-Eden filed a shelf registration with the SEC to sell up to 5M common shares and warrants, after withdrawing an unallocated shelf registration statement covering 3M shares. The value is based on the proposed maximum offering price.

31. Immtech filed to sell up to 1.5M shares from time to time. The value is based on the Aug. 25 closing stock price.

32. Introgen filed to sell up to $100M worth of its common stock from time to time.

33. NaPro filed a shelf registration statement to offer and sell up to 6.5M shares of common stock at $1.24 per share and 1M shares of preferred stock at $8.06 per share, according to the proposed maximum offering prices.

34. Neose filed a shelf registration statement to offer and sell up to $75M of its common stock from time to time.

35. Neurocrine filed a $200M shelf registration statement.

36. Neurogen filed for a $75M universal shelf registration statement.

37. Northfield filed a shelf registration statement with the SEC to offer and sell up to $50M of its securities from time to time. It privately placed $10.6M in shares in July.

38. Novavax filed to sell up to $50M in stock from time to time.

39. Nuvelo filed a shelf registration statement to offer up to $50M worth of common or preferred stock, or debt securities, from time to time.

40. The value of Pain Therapeutics' offering, $51.6M, is based on the Aug. 21 closing stock price of $6.70. The underwriters have an overallotment option for 1.1M shares.

41. Pharmos filed a shelf registration statement to sell up to $25M of common stock, preferred stock, debt securities and/or warrants. The company raised $4.3M in a private placement in March.

42. Progenics filed a shelf registration statement to offer and sell up to 2.75M common shares. The value is based on the proposed maximum aggregate offering price.

43. SciClone's underwriters would have an option to purchase up to an additional 900,000 shares to cover overallotments. The value is based on the proposed maximum offering price.

44. StemCells filed with the SEC to sell up to 15M shares to raise a maximum of $37.8M. Further details were not disclosed. The company privately placed $6.5M in shares in May.

45. Targeted Genetics filed to sell up to 11.6M shares of common stock from time to time. The value is based on the proposed maximum offering price.

46. Tularik filed to sell up to $250M in common stock and debt securities. It raised $27.2M in October 2002 with an offering of 4M shares. As of May, $217.8M remained available on the registration statement.

47. VaxGen filed a shelf registration statement for $150M in common stock, preferred stock, debt securities and warrants. Further details were not disclosed. It privately placed $5M in stock in May, and $7M in June.

48. Vical filed a shelf registration statement with the SEC that would allow it to issue, from time to time, an aggregate of up to $50M of common stock, preferred stock or a combination of both.

49. XOMA filed a registration statement to sell up to 13M shares of stock from time to time.

50. ZymoGenetics filed a shelf registration statement to offer and sell up to $150M of common stock from time to time.